Electronic Signature Rule Costs Offset By Efficiencies, FDA Tells PhRMA

The costs of implementing FDA's final rule on electronic records and signatures "are significantly offset by the substantial benefits to be realized by using trustworthy and reliable electronic records and electronic signatures," FDA told the Pharmaceutical Research & Manufacturers of America.